Skip to main content
. 2015 Apr 19;6(15):13334–13346. doi: 10.18632/oncotarget.3871

Figure 1.

Figure 1

A. RAL and RAS activity assays using lysates obtained from SW480 (KRAS mutation in codon 12), HCT116 (codon 13) and HT29 (KRAS wild-type, BRAFV600E mutation) cells (+: positive control; -: negative control). B. TaqMan RT-PCR analysis of RALA mRNA levels in the same cells following RALA knock-down using siRNA described by [27] and controls (p < 0.05). (C) RALA activity assay following knock-down (SC: scramble siRNA transfected control, KD: RALA knockdown, M: mock - transfection reagents only).